The Office of Technology Licensing was established in 1970 to transfer technologies developed at Stanford. Find out more about OTL's history, mission, staff, and statistics.

Login to TechFinder » 

Immunoassay for ADMA as a cardiovascular risk factor


Stanford Reference:

02-197


Abstract


Stanford University researchers have developed a novel derivatizing method that allows for the accurate detection of asymmetric dimethylarginine (ADMA) with increased sensitivity.

ADMA acts by inhibiting the production of nitric oxide (NO), which plays a vital role in vascular homeostasis and atherogenesis. Thus, increased levels of ADMA correlate to increased platelet aggregation, smooth muscle proliferation and adhesion molecule expression, which can lead to various cardiovascular diseases. As a result, ADMA has been identified as an important factor in assessing risk for cardiovascular diseases.



Applications


  • Method of detecting ADMA to assess cardiovascular risk in patients
  • Separation of isoforms of dimethylarginine for research into intracellular ADMA levels in diseased states

Advantages


  • Detects low levels of ADMA with higher sensitivity and accuracy

Innovators & Portfolio



Patent Status



Date Released

 4/11/2013
 

Licensing Contact


Chu Chang, Licensing Associate
650-723-0652 (Direct)
Login to Request Information

91-095 Monoclonal Antibody for Hypocretin-1 (MAb 310)
95-115 Novel fluorescent probe Cy7-APC
96-103 εPKC Agonists to Provide Cardioprotection

more technologies

Related Keywords


diagnostic: assay   diagnostic: immunoassay   cardiovascular   diagnostic: elisa   
 

   

  

Also of Interest...
91-095 Monoclonal Antibody for Hypocretin-1 (MAb 310)
95-115 Novel fluorescent probe Cy7-APC
96-103 εPKC Agonists to Provide Cardioprotection

Recently Viewed...
S02-197 Immunoassay for ADMA as a cardiovascular risk factor